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rendering them susceptible to transformation, the specific genes expressed are not yet known. Here, by identifying the genes
overexpressed in pluripotent rhesus ESCs (nhpESCs) and comparing them both to their genetically identical differentiated
progeny (teratoma fibroblasts) and to genetically related differentiated parental cells (parental skin fibroblasts from whom
gametes were used for ESC derivation), we find that some of those overexpressed genes in nhpESCs cluster preferentially
on rhesus chromosomes 16, 19, 20, and X, homologues of human chromosomes 17, 19, 16, and X, respectively. Differentiated
parental skin fibroblasts display gene expression profiles closer to nhpESC profiles than to teratoma cells, which are genetically
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in neurogenesis, have been identified. The overexpression of some of these genes discovered using pedigreed nhpESCs derived
from prime embryos generated by fertile primates, which is impossible to perform with the anonymously donated clinically
discarded embryos from which hESCs are derived, independently confirms the importance of chromosome 17 and X regions in
pluripotency and suggests specific candidates for targeting differentiation and transformation decisions.
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Human embryonic stem cell (hESC) research is invaluable in
discovering early developmental mechanisms and funda-
mental principles in pluripotency and differentiation. In
addition, hESCs hold great promise for clinically relevant
insights into the causes of diseases and perhaps even
improved treatment strategies (Dhara and Stice, 2008;
Menendez et al., 2006; Mountford, 2008; Unger et al.,
2008; Wang et al., 2008; Xu et al., 2006; Ben-Yehudah et al.,
2004). Notwithstanding the great significance of the current
basic and translational investigations, the origins of, and
strength of, evidence for hESCs differ strikingly from their
murine counterparts. Mouse ESCs were derived from blas-
tocysts obtained from genetically pedigreed fertile mice
(Evans and Kaufman, 1981; Tremml et al., 2008; Bryja et al.,
2006). The pluripotency of mESCs was unequivocally dem-
onstrated by mESC contributions to mouse offspring,
including germ-line transmission (Tremml et al., 2008;
Bryja et al., 2006) through the transfer of chimeric embryos
generated by mixing mESCs with mouse morulae or blas-
tocysts (Bryja et al., 2006). In contrast, existing human ESCs
were derived from embryos surplus to requirements for
assisted reproduction (Menendez et al., 2006; Mountford,
2008; Yu and Thomson, 2008; Hyun et al., 2008). To ensure
patient confidentiality, the established hESC lines are
anonymous, so neither pedigree analysis nor investigations
between or among closely related lines have been possible.
Pluripotency with hESCs has been demonstrated by
detection of specific markers as well as in vitro and in vivo
differentiation in teratomas; intraspecific chimera investi-
gations, on the other hand, raise significant ethical concerns
(Hyun et al., 2008; Deb et al., 2008; Pera et al., 2000; Talbot
and Blomberg le, 2008). However, though hESCs are similar
in their global characteristics, heterogeneity exists in gene
expression among the various hESC lines (Allegrucci and
Young, 2007). Regardless of these hESC limitations, vital
insights into the particular genes expressed during pluripo-
tency and the expression profile switches during differenti-
ation are swiftly emerging with profound implications for
induced pluripotency (iPS) cells (Lowry et al., 2008;
Takahashi et al., 2007; Yu et al., 2007; Brambrink et al.,
2008; Park et al., 2008). Recently, patient-specific plurip-
otent stem cells (PSCs) have been established (Choi et al.,
2009), providing the foundation both for in vitro clinical
disease models and for potentially immune matched lines for
transplantation.
Recently, we established 10 pedigreed nonhuman primate
ESC (nhpESC) lines from prime embryos conceived using
gametes from fertile breeders (Navara et al., 2007). In
contrast to hESCs but similar to mESCs, this panel of nhpESCs
is extremely homogeneous in its gene expression profiles
(N97% identity between and among lines). These pedigreed,
partially inbred, well-characterized nhpESCs were then used
to assess a more comprehensive list of stemness genes
without the interference of unknown or heterogeneous
genetic backgrounds. Due to our knowledge of the parental
pedigrees of these ESCs, we were able to isolate skin
fibroblast from the monkeys from which gametes were
obtained for establishing these nhpESCs.
hESCs have been found to display predispositions toward
aneploidities on chromosomes 12, 17, 20, and X (Gertow etal., 2007; Imreh et al., 2006; Draper et al., 2004; Lefort et
al., 2008; Spits et al., 2008; Hanson and Caisander, 2005),
though the expressed genes are not yet known. These
predispositions render hESCs susceptible to transformation
(Werbowetski-Ogilvie et al., 2009), which jeopardizes their
utility as biological resources for in vitro investigations and
undermines their clinical reliability in patients after trans-
plantation. This investigation sought to identify the genes on
the homologous nonhuman primate (NHP) chromosomes.
Using a battery of ESCs from pedigreed fertile nonhuman
primates, in this study we compared the gene expression
profiles of these fully differentiated cells to nhpESCs as well
as to fibroblasts isolated from teratomas derived from these
nhpESC, i.e., genetically identical fully differentiated cells.
We found that some of the genes overexpressed clustered
preferentially on rhesus chromosomes 16, 19, 20, and X,
homologues of human chromosomes 17, 19, 16, and X,
respectively (Gibbs et al., 2007). The overabundance of
overexpressed genes on chromosomes 17 and X indepen-
dently confirms the importance of these chromosome regions
in pluripotency and suggests specific candidates for targeting
transformation decisions.Results
To overcome the genetic background heterogeneity which
might mask some aspects of the actual stemness signature,
we utilized a newly established bank of pedigreed nhpESCs
(Navara et al., 2007) to generate a unique nonhuman primate
“stemness gene” list generated by the comparison of nhpESC
gene expression to two different sources of genetically
identical or genetically related differentiated fibroblasts.
The first were grown out of skin explants taken from the
nonhuman primate parents from which gametes were used to
generate the stem cell lines. The second were teratoma
explants. The pedigree of the different types of cells is
depicted in Fig. 1A. For Figs. 1B and 1C, RNA was isolated
from all three types of cells: (1) skin fibroblasts; these
samples are indicated by the letter M (monkey) before the
monkey identification number and sample label (a–f; 2)
nhpESCs denoted by C (cell line) followed by the cell line and
sample; (3) fibroblast explants from teratomas generated by
the injection of nhpESC into immune-compromised mice.
Since there were a number of teratomas for every stem cell
line, we designated the nomenclature as follows: T (terato-
ma)–number of teratoma from the line–line name–sample.
Therefore, TA31b denotes that this is the second sample of
the first teratoma from line 3106.
The accuracy of findings in stem cell research is subject to
considerations regarding the purity of the cellular popula-
tions. We verified the quality of our cellular populations in
several ways. First, we showed that the nhpESC lines can
generate teratomas that consist of tissues from all three
germ layers (Supplementary Fig. 1). We also analyzed the
teratoma sections for OCT-4 detection; the observations that
they did not react with OCT-4 antibodies, while control
seminomas did, demonstrate that they did not harbor
pluripotent cells. Were they to contain pluripotent stem
cells as a contaminant, our ability to detect pluripotent gene
expression would have been compromised. We never
identified OCT-4-positive cells within teratomas derived
Figure 1 Genes expressed in pluripotent ESCs differ significantly from their genetically identical differentiated fibroblasts. (A)
Experimental design. Gene expression profiles of three different cell types were compared: pluripotent nhpESCs (lines C3106 and
C3806), their pedigreed parents, and their differentiated progeny in teratomas denoted by the letter T followed by the teratoma
number and cell line from which it was derived. Teratoma images are panoramic views at a 4× magnification after H&E staining. (B)
Heat map of clustering described in C. Thirty-nine (6 stem cell samples, 24 teratoma and 9 skin fibroblast) were analyzed for gene
expression using Affymetrix Rhesus gene expression chips. We applied agglomerative hierarchical clustering to the gene expression
values, using the minimum variance incremental sum of squares method of Ward (Gordon, 1999), with dissimilarity measured by one
minus the squared Pearson correlation. Yellow, relatively overexpressed; purple, relatively underexpressed. Color scale is in log ratio
to the overall mean of the row. (C) Clustering analysis of 29 000 genes with an Entrez gene ID described in B. The three cell types
clustered together with their cellular subtype: pluripotent nhpESCs were significantly different from both types of differentiated
fibroblasts. In addition, skin fibroblasts clustered together and separated from the teratoma-derived lines in two distinct nodes.
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Table 1 Genes significantly overexpressed or underexpressed in pluripotent nhpESCs compared to differentiated parental or
progeny fibroblasts
a Pluripotent marker; b membrane protein; c transcription factor; d associated with neuronal development or function. Red, yet
uncharacterized gene. Yellow, overexpressed. Pink, underexpressed genes in nhpESC compared to fibroblast.
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minor cell type) could we find Oct-4-positive cells in
teratomas derived from line 3806 (Supplementary Fig. 2).
Furthermore we examined cellular karyotypes, to ensure
that the cells we investigated were euploid. Supplementary
Figs. 3 (line 3106) and 4 (line 3806) show that both the
nhpESC lines and the teratoma fibroblasts have normal
karyotypes and that the teratoma karyotypes fit the nhpESC
lines from which they have been derived. While the teratoma
and nhpESC have an identical genome, it is only 50% identical
to the parental skin fibroblast. We investigated both male
(3106) and female (3806) nhpESC lines to eliminate geneticbackground, as well as to examine the effects of sex on the
differences in gene expression.
After mRNA isolation and hybridization to Affymetrix
rhesus arrays, we examined the gene expression profiles of
these cells. A heat map (Fig. 1B) was generated using cluster
analysis and, as expected, the nhpESC displayed a highly
different gene expression profile from both types of
fibroblasts. When clustering the single samples using all
∼53 000 probes on the array (Fig. 1C), we found that the
three cell types clustered together with their cellular
subtype: pluripotent nhpESCs were significantly different
from both types of differentiated fibroblasts. In addition, we
29Chromosome localization of pluripotency genesfound that the skin fibroblasts clustered together and
separately from the teratoma-derived lines in two distinct
nodes. These results indicate that although both were
fibroblasts, they were not identical cells. In addition, Fig.
1C shows the internal quality of our results since the three
independent samples from each cell sample usually clustered
together with its replicates. Out of the triplicates used for
each experiment, we omitted one outlier of the ES samples
(C3806c) since its gene expression differed extensively from
all other nhpESC samples, as shown in the heat map
illustrated in Supplementary Fig. 5.
We next analyzed the genes that are significantly
different between nhpESC and both types of fibroblasts.
We found that out of the 28 895 annotations with an entrez
gene ID, 8252 annotations differ between the two groups. No
significant changes were detected between male and female
cells (data not shown), indicating that the differences were
greater between cell types (nhpESC versus fibroblast) than
between sexes. As expected, we found that Oct-4, Nanog,
and Sox-2 that have been associated with pluripotency were
among the 20 most up regulated genes in nhpESC compared
to both types of fibroblasts (depicted in Table 1 and Fig. 2A).
However, many of the genes that were either up regulated or
down regulated are still not characterized in the rhesus, and
their study will lead to further insights into pluripotency
characteristics. In addition, to our surprise, we found that
15% of the most up regulated genes were associated toFigure 2 Differentially expressed genes are detected by gene
expression arrays and qPCR. (A) Plotting gene expression levels
on the microarray. Black bars denote stem cells, white bars skin
fibroblast, and gray bars teratoma fibroblast. For each expres-
sion level at least 5 samples were used. (B) For verification of
array information, we used quantitative-PCR assay. Results
denote at least 3 experiments for at least 2 cell lines. Blue, Sox2;
Red, Oct4; Yellow, Nanog. Error bars, SD.neurogenesis (according to OMIM). No apoptosis-associated
proteins were observed, and consequently it seems unlikely
that contact inhibition or apoptosis was significantly differ-
ent between the cell types.
We confirmed these differences in pluripotent markers
between cell lines using quantitative PCR (qPCR; Fig. 2). For
these experiments, we used the same RNA extracted for the
gene arrays for consistency. We used two samples from each
cell type and averaged results of the samples are shown in
Fig. 2B. While Nanog was not detected in either group of
fibroblasts, OCT-4 was expressed in low levels, and SOX2 was
expressed in low levels in the teratoma fibroblasts; this is
similar to the gene array expression differences between
both types of fibroblasts (Fig. 2A).
Using Ingenuity software we found that a large number of
pathways were differentially expressed between stem cells
and both types of fibroblast. Ingenuity constructs systems
networks by analyzing our data together with its scientific
literature-based software. Among the networks which are
differentially expressed between pluripotent and differen-
tiated cells are mitochondria dysfunction gene networks, as
well as those involved in the G2/M transition (Supplementary
Fig. 6). It has been established that stem cells are better
maintained in a low oxygen environment (Ezashi et al.,
2005). In addition, stem cells appear to have less stringent
cell cycle checkpoints. Both phenomena might be explained
by the enriched pathways in stem cells compared to
fibroblast depicted in Supplementary Fig. 6.
To test whether genes over- or underexpressed in nhpESCs
lie more—or less—often on certain macaque chromosomes
than expected by chance we used chi-squared to test the
goodness of fit (GOF) of the observed counts of differentially
expressed genes on all 22 chromosomes to the expected
counts based on the distribution among chromosomes of all
probes on the chip with chromosomal attributions. Supple-
mentary Table 1 shows a representative analysis of confidence
values for the respective chromosomes using chi-squared
“goodness of fit (GOF)” with a P value of 10-4. Additional
statistical analyses using other models and P values were also
performed. Having obtained statistically significant results
with the omnibus GOF test, we used Bonferroni to control the
familywise error rate at 0.05 in binomial proportions testing to
detect over- or underabundances of differentially expressed
genes on chromosomes (Fig. 3A). We found that there is an
overabundance of overexpressed genes on chromosomes 16,
19, 20, and X that correlate to the human chromosomes 17,
19, 16, and X, respectively. Interestingly, of these 4
chromosomes 2 have previously been shown to undergo
aneploidities in prolonged hESC tissue culture conditions.
Rhesus chromosomes 6 and 12 were shown to be under-
expressed in our experiments (Fig. 3B). These results are in
agreement with previous published results showing chromo-
somal instability in rhesus preimplantation embryos (Dupont
et al., 2009a,b). When global gene expression patterns were
characterized, we found that the nhpESC gene expression was
closer to skin fibroblasts rather than to the teratoma
fibroblasts, although genetically they share their genome
with teratoma fibroblasts and only half with skin fibroblasts.
We identified a stem cell signature that would define a
pluripotent cell by its relative average gene expression for all
genes. We examined the average log relative gene expres-
sion of both the 29 000 genes with a known gene Entrez gene
Figure 3 Chromosome overabundance of gene expression. Genes overexpressed in nhpESC are clustered on rhesus chromosomes 16,
19, 20, and X and underabundant are clustered on rhesus chromosomes 6 and 12. (A) Ratio of overexpressed genes observed divided by
the overexpressed genes expected calculated by the ratio of annotations for each gene on the array is shown by the bars. Significance
is indicated by the orange graph (-log (P value)). Only differentially expressed genes with an Entrez gene ID and a chromosome location
were analyzed. (B) Ratio of underexpressed calculated as in A.
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nhpESC and fibroblasts (data not shown). We found that the
overall relative gene expression of the fibroblast was indeed
significantly higher than in the nhpESCs. Interestingly, the
relative expression of the skin fibroblast was closer to the
nhpESC than to the teratoma fibroblasts. Using BRB
ArrayTools we could visualize a 3-D relationship among the
3 groups of cells illustrated in Fig. 4B, in which nhpESC were
closer in gene expression to skin fibroblasts than to teratoma
fibroblasts. This 3-D analysis permits rotation of the datasets
so that their interrelationships can be viewed from various
perspectives. These effects were independent of sex.
Finally, we have compiled system networks inferred to
regulate the pluripotent ↔ differentiation transition in
nonhuman primate stem cells (Fig. 5). It is important to
note that this list is generated totally independently of the
list of “stemness genes” which have been identified in the
more heterogeneous human ESCs. Anticipated candidate
genes include SOX2, OCT-4, and NANOG, while unanticipated
genes include up regulation of IL17. Interestingly, we found
that many genes, such as members of LHX and DLX families of
genes, were down regulated in nhpESCs. Both gene families
have been shown to be involved in fetal development (Hardt
et al., 2008; Kraus and Lufkin, 2006; Woodside et al., 2004).Discussion
Pluripotent stem cell (PSC) research, which emerged from
the intensive investigations on embryonic stem cells, hastremendous importance for understanding fundamental
concepts of early development, differentiation decisions,
and cell proliferation controls. Now with the intense focus on
human PSCs, this previously fundamental science is rapidly
moving toward more clinically relevant arenas. These fields
include PSC differentiation for cell replacement, PSC
progenitors of cancer, patient-specific and/or disease-
specific induced PSCs for mechanistic and drug discoveries.
These proposed medical implications of pluripotent stem
expression patterns in human PSCs now demand increased
scrutiny to assure that the discoveries are indeed accurate
and unaffected by inherent biological and genetic limita-
tions, i.e., the heterogeneity of the existing hESC lines; their
suboptimal origins from clinically discarded embryos con-
ceived in vitro by infertility patients; their genetic anonym-
ity; their extensive propagation in vitro; among others. To
address these concerns, we have conducted a completely
independent analysis of “stemness” gene networks using
pedigreed rhesus ESCs derived from fertile primates (Navara
et al., 2007). Because these datasets do not rely on the
existing hESC stemness gene expression patterns, it is
noteworthy that the most prominent pluripotency genes,
i.e., SOX2, OCT-4, and NANOG, emerge as dominant
regulatory factors. In addition, unexplored candidate genes
may be worthy targets for further research attention.
To ensure that we did not have contaminations of
differentiated cells within our undifferentiated cultures, or
undifferentiated cells within our differentiated cultures, we
routinely stained our undifferentiated cultures with “stem-
ness markers,” i.e., OCT-4, NANOG, SSEA-3, and -4, as well
Figure 4 Gene expression averages of skin fibroblast are more
closely related to pluripotent nhpESCs than genetically identical
fibroblasts differentiated within teratomas. (A) Box plot of
average gene expression. Dark solid lines show median expres-
sion level off all genes in each group. The interquartile range
(IR), or middle 50%, of average gene expression is delimited by a
box. Data are expressed on a log base 2 scale. (B) Snap shots
from a 3-D analysis using BRB ArrayTool show that nhpESC are
different from both types of fibroblast (left), nhpESC are similar
to skin fibroblast but different from teratoma fibroblast
(middle), and the 3 groups are slightly different from each
other (right). Sex of the cells did not affect results. Red, male
nhpESC; green, female nhpESC; pink, male teratoma fibroblast;
pink, female teratoma fibroblast; cyan, male skin fibroblast;
blue, female skin fibroblast.
31Chromosome localization of pluripotency genesas neuronal markers (data not shown). In addition, as
depicted in Supplementary Fig. 2, we could not find OCT-4-
positive cells within the teratomas generated from line 3106,
and only very rarely from those generated from line 3806.
Since a possibility of “contamination” exists, a pure
population of FACS sorted cells would be the ideal population
for these experiments. However, since most nhpESC die in a
single cell population, we refrained from FACS sorting. In
addition, we grew both skin and teratoma fibroblasts for N4
passages before extracting their RNA to ensure as pure a
population of fibroblasts as possible.
When global gene expression patterns were character-
ized, we found that the nhpESC gene expression was closer to
skin fibroblasts than to teratoma fibroblasts, although
genetically they share their genome with the teratoma
fibroblast and only half with skin fibroblasts. These results
might indicate that the cells isolated from the skin andcharacterized as fibroblasts might harbor less well differen-
tiated cells closer in their gene expression to authentic
undifferentiated cells. Perhaps this result might shed light on
the success rate of skin fibroblast to form iPS cells as
compared to other types of cells (Lowry et al., 2008;
Takahashi et al., 2007; Yu et al., 2007; Brambrink et al.,
2008; Park et al., 2008).
Although most of the genes depicted in Table 1 are
unidentified, some of the differentially expressed genes are
associated with pluripotency, such as Oct-4 and Sox-2. In
addition, others could be found in future research to play
roles in regulating the pluripotency ↔ differentiation
transitions. For example, TACSTD1, also called CD44 or Ep-
CAM, is an epithelial adhesion molecule that was originally
identified as a marker of carcinomas (Baeuerle and Gires,
2007; Trzpis et al., 2007). We found this gene to be the most
differentially expressed gene between stem cells and
fibroblasts, indicating that it might have other functions in
signaling rather than solely adhesion. In contrast, decorin
(DCN) has an important role in maintaining the balance in
Peyronie's disease (PD) where fibrotic plaques are formed.
DCN neutralizes one of the causes for plaque formation—
transforming-growth-factor β1 (Gonzalez-Cadavid and
Rajfer, 2005). Consequently it is perhaps not surprising
that DCN was underexpressed in the pluripotent stem cells
we examined.
To identify “stemness genes” a comparison between gene
expression of pluripotent cells to their in vitro differentiated
counterparts was carried out (Sato et al., 2003; Zeng et al.,
2004). While genetic background is identical, the presence of
some undifferentiated or partially differentiated cells
cannot be ruled out. In contrast, a range of undifferentiated
cells can be used for the common denominator[s] that
defines the pluripotent state (Sato et al., 2003; Bhattacharya
et al., 2004, 2005; Cai et al., 2006; Ivanova et al., 2002;
Ramalho-Santos et al., 2002; Sperger et al., 2003), or the
comparison of gene expression between and among different
stem cell lines. These experiments usually showed that hESCs
are quite different from each other (Allegrucci and Young,
2007; Navara et al., 2007; Abeyta et al., 2004; Rao et al.,
2004). A more comprehensive study showed that although
closely related, the 59 ESC lines showed heterogeneity in
gene expression (Adewumi et al., 2007). Interestingly,
variations in gene expression were found not only in genes
correlated with the pluripotent state or differentiation, but
also in the expression of housekeeping genes (Synnergren et
al., 2007). Therefore, interactions among many genes
forming an active network that will allow the pluripotent
state to be maintained are likely at work (Vogel, 2003).
The first two studies that characterized the “stemness
gene” list (Ivanova et al., 2002; Ramalho-Santos et al., 2002)
identified about 250 putative genes involved in mESC
pluripotency, and many other genes are being studied
today (Allegrucci and Young, 2007; Bhattacharya et al.,
2004, 2005; Cai et al., 2006). Stemness gene lists have been
generated by comparing different types of pluripotent cells
(Kim et al., 2006) or by comparing differentiated cells to
differentiated cells (Bhattacharya et al., 2005; Cai et al.,
2006; Golan-Mashiach et al., 2005; Liu et al., 2006; Shin et
al., 2007; Beqqali et al., 2006; Lee et al., 2007). It is
interesting to note that OCT-4 is on chromosome 6p21.33,
SOX-2 3q26.3, and NANOG 12p13.31, so none of this
Figure 5 System analysis using ingenuity. Ingenuity analysis shows that while known players of stemness (Nanog and Sox-2) are
overexpressed (red) in nhpESC compared to fibroblast, many other genes are expressed as well indicated by the red tint. Genes
denoted by the green tinge are overexpressed in fibroblast. For this analysis we compared all genes with a known entrez gene ID.
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expressed chromosomes found here. Further analysis is
underway to identify these pluripotency regulatory clusters.
It has been well established that a number of key proteins
play an important role in the maintenance of pluripotency in
both mESCs and hESCs, such as OCT-4, NANOG, and SOX2
(Sato et al., 2003; Zeng et al., 2004) as well as the existence
of a regulatory network in mESC (Zhou et al., 2007) for SOX2
(Masui et al., 2007; Stanton and Bakre, 2007), OCT-4 (Babaie
et al., 2007), and NANOG (Pan and Thomson, 2007). Similar
results were shown in hESCs since hESCs treated with RNAi
against SOX2 cells readily differentiated (Fong et al., 2009).
Although there is much information on the cooperation
activity of OCT-4, NANOG, and SOX2, we still lack informa-
tion regarding other key players in the maintenance of the
pluripotent state.
To better understand the extensive list of genes involved
in the differences between cell lines, research has been
conducted on specific pathways that are differentiallyexpressed. Rho et al. (Rho et al., 2006) found that the
Wnt, Hh, Notch pathways but not the JAK/STAT had
overabundant transcripts in ESC compared to EBs. Therefore
they concluded that self-renewal is a coordinated signaling-
specific mechanism. In addition, Li et al. (Li et al., 2006)
identified a transcriptome involved in this differentiation
process. Still, most genes that are differentially expressed
have yet to be identified (ESTs) or have not been correlated
with pluripotency (Robson, 2004). Studying them will
enhance our understanding of the pluripotent state.
In order to achieve an orchestrated pathway in develop-
ment, a well coordinated machinery must be activated to
turn off pluripotent genes and turn on the expression of
differentiation genes. This process is usually carried out by
transcription factors as shown in mESCs (Hailesellasse Sene
et al., 2007) and hESCs (Laslett et al., 2007). These
transcription factors can together form a hierarchy in a
complex network that maintains the pluripotent state (Kim
et al., 2008) and include reprogramming factors used for iPS
33Chromosome localization of pluripotency genes(OCT-4, SOX2, KLF-4, and c-MYC) as well as NANOG, DAX-1,
REX-1, ZPF281, and NAC-1. Other DNA remodeling proteins
have been associated with pluripotency in mESC (Zhou et al.,
2007) and both the similarities and the differences between
the mouse networks generated by Zhou et al. (Zhou et al.,
2007) and ours are informative. Both found genes not yet
appreciated as regulators of pluripotency.
Recently, new mathematical algorithms have been
developed to help identify pluripotent genes (Grskovic et
al., 2007). Analyses using them showed that every hESC has
its unique signature but shares many genes with other hESC
lines that help maintain the pluripotent state (Suarez-
Farinas and Magnasco, 2007; Suarez-Farinas et al., 2005;
Rao and Stice, 2004). However, that analysis was based on
the comparison of three hESC lines that, although similar,
still contain many differences (Abeyta et al., 2004).
While many studies have been carried out on mESC and
hESC, very few have searched for pluripotent genes in
nhpESC. A single study has compared rhesus ESC to EBs
(Byrne et al., 2006). They identified 367 genes that were
expressed in 5 nhpESC lines and include CCNB1, GDNF3,
LeftB, OCT-4, and NANOG. These 367 genes may represent
the stemness core allowing the cells to maintain the
pluripotent state.Conclusion
The prominent stemness triad of SOX2/OCT-4/NANOG found
in pluripotent human stem cells is the dominant regulatory
network in primate PSCs. This confirmation is reassuring
since it suggests that the hESC lines' heterogeneous origins—
embryos discarded by anonymous infertility patients—do not
compromise the fundamental utility of the existing lines.
Needless to say, newer, more robust, and more diverse lines
would accelerate research discoveries. Differences between
gene expression profiles in human lines compared with
primate ones may prove instrumental in discovering the
genetic basis of certain forms of infertility which might have
been transmitted to the resultant hESCs. Also, since the
majority of these lines came from Indian rhesus monkeys, the
subspeciation of this group could be further analyzed.
Finally, the preferred clustering of overexpressed genes on
the NHP homologues of human chromosomes 17, 19, 16, and
X highlights the centrality of these regions to pluripotency
and suggests that investigating the role of these genes may
further enhance our understanding of the mechanisms that
determine stemness and pluripotency.Materials and methods
The overall strategy to identify the genes overexpressed and
underexpressed in pluripotent stem cells and, if clustered on
chromosomes, to localize those chromosomes is depicted in
Fig. 1. Pluripotent pedigreed rhesus ESCs (female ESC line
C3806 – black circle; male ESC line C3106 – black square)
were compared to genetically identical differentiated
progeny grown from their resultant teratomas (five male
teratomas and three female teratomas: ‘T’, i.e., TA31, TB31,
TC31, TD31, TE31, and TA38, TB38, TC38, respectively) aswell as to differentiated cells from their macaque parents
(‘M’).
Teratoma formation and fibroblast isolation
Stem cell pluripotency potentials were assessed by teratoma
formation in SCID mice. Nonhuman primate ESCs (nhpESCs)
were isolated by scraping colonies with good morphology and
using a brief 5-min treatment with 0.25% trypsin/EDTA to
break up large fragments. Cells were pelleted at 800g for
10 min and washed twice in sterile PBS, and approximately
5×105 – 5×106 cells were injected into the testis of 8- to 12-
week-old NOD-SCID mice (Jackson Labs) by modification of
efferent duct injection (Ogawa et al., 1997). The injection
pipette was advanced along the efferent duct and through
the rete testes into the interstitial space where cells were
injected (using Eppendorf Femtojet). The injection itself
was monitored with trypan blue added to the cell suspension.
Tumor growth was determined by palpation and was typically
detectable 10–12 weeks after injection. Teratomas were
dissected from euthanized mice placed in tissue culture (for
the isolation of outgrowths) or fixed (for pathological
examination). For tissue culture (skin or teratoma), cells
were minced into small fragments and maintained in
fibroblast media (DMEM containing 10% FBS, penicillin/
streptomycin, L-glutamine, nonessential amino acids) for 7
days before media replacement to ensure attachment of
cells. In all fibroblast experiments (both skin fibroblast and
teratoma fibroblast) cells were cultured for N4 passages
before RNA isolation. All RNA was isolated when cells were
∼80% confluent to ensure that cells were proliferating, and
therefore unaffected by contact inhibitor. For pathological
examination, teratomas were fixed in 4% paraformaldehyde,
paraffin embedded, and examined histologically after
Hematoxylin and Eosin (H&E) staining. Isolated tumors
were identified as teratomas if tissues derived from all
three germ layers were identified in the sections.
Cytogenetic analysis to assay normal karyotype
Cytogenetic analysis was performed as described previously
(Navara et al., 2007).
Gene expression profiling
RNA extraction
Total RNA was extracted using the Trizol protocol (100 μl
/10×104 –105 cells) (Navara et al., 2007) and purified using
the Qiagen RNeasy Micro Kit (Valencia, CA) according to the
manufacturer's recommendations. RNA quantity and quality
were determined using a Nanodrop spectrophotometer and
Agilent Bioanalyzer (Navara et al., 2007).
Preparation of labeled cRNA
One microgram of total RNA was used to start the manual
target preparation using the Codelink Expression Bioarray
System (Amersham Biosciences/GE Healthcare). Briefly,
double-stranded cDNA synthesis was performed with a
T7oligo (dT) primer, followed by purification. This cDNA
was used as a template for in vitro transcription with biotin-
labeled nucleotides. Fifteen micrograms of the labeled cRNA
34 A. Ben-Yehudah et al.was hybridized to Affymetrix Rhesus Macaque genome 49
format Arrays (GeneChip Rhesus Macaque Genome Array,
Cat. No.900656, Affymetrix, Santa Clara, CA, USA), followed
by washing and staining with streptavidin phytoerythrin
(SAPE) as recommended by the manufacturer. Arrays were
scanned on an Affymetrix GeneChip 3000 Scanner. The arrays
contain 52 866 probe sets that represent ∼30 000 human
orthologues and ESTs. Affymetrix GCOS software was used
for the scanning of the probe arrays and the probe intensity
analysis and normalization was performed using RMA express
(Navara et al., 2007).
Microarray data analysis
The gene expression analysis protocol has been previously
described (Kaminski and Friedman, 2002). Statistical analysis
was performed using the Scoregene gene expression package
(http://www.cs.huji.ac.il/labs/compbio/scoregenes), and
data visualization was performed using Genomica (http://
genomica.weizmann.ac.il) (Segal et al., 2004), Spotfire
Decision Site 8.0 (Spotfire Inc. Göteborg, Sweden), Treeview
(http://jtreeview.sourceforge.net), and BRB ArrayTools
(http://linus.nci.nih.gov/BRB-ArrayTools.html). The RMA
output for every gene was divided by the geometric mean
of all the values for the same gene and was log base 2
transformed. In the analysis we only included transcripts
with locus link numbers. To determine the differentially
expressed genes we used t test or significance analysis of
microarrays (SAM). In the clustering we included only genes
that had a q value=0 in both scoring methods. This criterion
was also employed for assessing over- and underabundant
expression. FDR analysis was carried out as described
(Navara et al., 2007).
RNA extraction, quantitative-PCR, and TaqMan
low-density arrays
Cells were collected and pelleted. Total RNA was extracted
using Trizol reagent (Invitrogen) and treated with RNase-free
kit (Ambion, Austin, TX). PCR mixtures were prepared using
an IMPROM- II reverse transcription system (Promega,
Madison, WI) following the manufacturer's instructions.
qPCR was performed using an ABI Prism 7700 (Applied
Biosystems Incorporated, Foster City, CA). Taqman gene
expression assays (Applied Biosystems) were used for
NANOG, OCT-4, and β actin. Water and no RT samples
were used as control. All samples were run in triplicate.
TaqMan Array human stem cell Pluripotency Panel (Applied
Biosystems) was used following the manufacturer's instruc-
tions. Real-time PCR expression data from 96 genes was
analyzed. Six genes were endogenous controls, and 30 genes
were not included in our analysis due to very poor
amplification in any sample. mRNA fold changes were
calculated using the -ΔΔCt method and normalized using β
actin expression as endogenous control.
Immunohistochemistry
Paraffin-imbedded tissue was deparaffinized and hydrated
by incubating sections in three washes of xylene for 5 min
each, followed by two washes of 100% ethanol for 10 min
each, two washes of 95% ethanol for 10 min each, and twowashes in dH2O for 5 min each. Antigens were retrieved by
boiling slides in 10 mM sodium citrate buffer, pH 6.0,
maintained at a subboiling temperature for 10 min and
cooled for 30 min. For staining, sections were washed in
dH2O three times for 5 min each, incubated in 3% hydrogen
peroxide for 10 min, and washed in dH2O twice for 5 min each
followed by washing buffer (1X TBS/0.1% Tween 20 (1X
TBST)) for 5 min. Sections were blocked with 400 μl blocking
solution (TBST/5% normal goat serum: to 5 ml 1X TBST add
250 μl normal goat serum) for 1 h at room temperature.
Primary antibody was added (OCT4; Cell Signaling Technol-
ogies) overnight at 4 °C. Antibodies were removed and
sections were washed in wash buffer three times for 5 min
each. The amount of 400 μl biotinylated secondary antibody
was added to each section and incubated 30 min at room
temperature. Sections were washed three times with wash
buffer for 5 min each. DAB was added to each section to
develop slides.
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